Capilano Honey first half profit exceeds Morgans expectations
Capilano Honey (ASX: CZZ) has delivered a solid result for the six months to December 31, 2016, a period in which it invested heavily in launching the world’s first prebiotic honey.
Consequently, the group’s ability to deliver year-on-year profit growth of circa 8% should be viewed favourably. It is also worth noting that the net profit of $5.9 million was ahead of the expectations of Morgans CIMB ($5.6 million).
This represents earnings per share of 62.2 cents, leaving the company well-placed to achieve Morgans full-year fiscal 2017 earnings per share forecast of $1.27 given that the broker was forecasting a stronger second half performance.
Capilano’s profitability continues to be driven by its local and international retail markets with market share from its domestic operations remaining constant. The export market had a decline in revenues due to lower sales in the bulk industrial segment, but recorded an increase in margins for overall export sales.
Capilano’s revenues are mainly generated from its domestic business, and these accounted for circa $55 million of group revenue which was in the order of $66.5 million.
In terms of outlook, Capilano said that it has always taken a very considered approach to achieving distribution and sales into China, a market that has presented challenges to other players in the food distribution market.
Managing Director, Ben McKee, highlighted the significance of understanding end markets in saying, “Having visibility of distribution so we can best manage the sales into this market to deliver sustainability, control and growth potential has been our priority”.
While the company has taken a measured approach in terms of exporting products to China, revenues from this market still grew by 87% in the first half.
It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.